Advanced Gastroesophageal Cancer
Publication Date: January 4, 2023
Key Points
Key Points
- Gastroesophageal cancers are among the most prevalent gastrointestinal malignancies worldwide. In 2020, there were over 1 million new cases and 769,000 deaths due to gastric cancer.
- Most gastric and gastrointestinal junction tumors are adenocarcinoma.
- Targeted cancer therapies and immunotherapy are more effective in subgroups of gastroesophageal cancer patients who possess certain biomarkers such as programmed death-ligand 1 (PD-L1) protein expression.
Treatment
...eatmen...
...e 1. Immunotherapy and Targeted Therapy for Adv...
...irst-line Ther...
...1.1For HER2-negative patients with...
...ommendation 1.2For HER2-negative patients with...
...mmendation 1.3For patients with ESC...
...ion 1.4For patients with ESCC, and PD-L1 tumo...
...on 1.5For patients with HER2-positive gastric o...
...- or Third-line Therapy...
...dation 2.1For patients with advanced gastroesopha...
...tion 2.2For HER2-positive patients with...